Chronotropic effect of D-Ala2,Leu5,Arg6 -enkephalin (dalargin) is associated with activation of peripheral κ-opioid receptors

Bulletin of Experimental Biology and Medicine

Volumn 140, Issue 6, 2005, Pages 682-686

  Maslov, L N ^a,b   Barzakh, E I ^a   Platonov, A A ^a   Minin, S M ^a   Ovchinnikov, M V ^c  

^a CARDIOLOGY RESEARCH INSTITUTE   (Russian Federation)

^b TOMSK STATE PEDAGOGICAL UNIVERSITY   (Russian Federation)

^c INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Dalargin; Heart; Opioid receptors

Indexed keywords

17 METHYLNALOXONE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; HEXAMETHONIUM; KAPPA OPIATE RECEPTOR; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; NALOXONE; NORBINALTORPHIMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BRADYCARDIA; CHOLINERGIC SYSTEM; CHRONOTROPISM; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GANGLION BLOCK; GENE ACTIVATION; HEART RATE; HYPOTHESIS; ISOLATED HEART; NONHUMAN; RAT; RECEPTOR BLOCKING; TACHYCARDIA; UREA CYCLE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ELECTROCARDIOGRAPHY; ENKEPHALIN, LEUCINE-2-ALANINE; HEXAMETHONIUM; MALE; MYOCARDIUM; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECEPTORS, OPIOID, KAPPA; TIME FACTORS;

ANIMALIA;

EID: 33644848492     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-006-0053-z     Document Type: Article

References (13)

1. R. N. Alyautdin, V. E. Petrov, A. A. Ivanov, et al., Eksp. Klin. Farmakol., 59, No. 3, 57-60 (1996).
2. N. V. Korobov, Farmakol. Toksikol., No. 4, 35-38 (1988).
3. Yu. B. Lishmanov and L. N. Maslov, Opioid Neuropeptides, Stress, and Adaptive Protection of the Heart [in Russian], Tomsk (1994).
4. Yu. B. Lishmanov and L. N. Maslov, Patol. Fiziol. Eksp. Ter., No. 1, 2-10 (2003).
5. Yu. B. Lishmanov, L. N. Maslov, and K. Rais, Eksp. Klin. Farmakol., 65, No. 4, 71-77 (2002).
6. L. N. Maslov, Yu. B. Lishmanov, I. V. Maksimov, et al., Klin. Farmakol. Ter., 13, No. 4, 47-52 (2004).
7. L. N. Maslov, N. A. Fedorova, V. A. Dudko, and R. S. Karpov, Ibid., 12, No. 4, 80-83 (2003).
8. D. S. Ugdyzhekova, L. N. Maslov, A. V. Krylatov, et al., Eksp. Klin. Farmakol., 64, No. 4, 17-20 (2001).
9. P. J. Birch, A. G. Hayes, M. J. Sheehan, and M. B. Tyers, Eur. J. Pharmacol., 144, 405-408 (1987).
10. B. N. Dhawan, F. Cesselin, R. Raghubir, et al., Pharmacol. Rev., 48, No. 4, 567-592 (1996).
11. L. N. Maslov, Y. B. Lishmanov, N. V. Solenkova, et al., Life Sci., 73, No. 7, 947-952 (2003).
12. R. J. Milne, J. M. Coddington, and G. D. Gamble, Neurosci. Lett., 11, 259-264 (1990).
13. N. Pencheva, J. Pospisek, L. Hauzerova, et al., Br. J. Pharmacol., 128, No. 3, 569-576 (1999).